Human Recombinant SARS-CoV-2 Spike Stable Cell Line
CHO-K1/Spike Stable Cell Line

Figure 1: FACS analysis of cell surface expression of SARS-CoV-2 spike protein on CHO-K1 cells. CHO-K1/Spike cells (red) and negative control CHO-K1 cells (grey) were probed using ACE-2 Fc Chimera, Human (Cat. No. Z03516, GenScript) and Alexa Fluor 647 conjugated Goat anti-Human IgG (H+L) Cross-Adsorbed Secondary Antibody (Cat. No. A-21445, Thermo Fisher).

CHO-K1/Spike Stable Cell Line

Recombinant CHO-K1 cells stably overexpress human SARS-CoV-2 spike protein on their surface. The surface expression of SARS-CoV-2 spike protein is validated by FACS analysis. This stable cell line product is designed for screening antibodies against the SARS-CoV-2 spike protein, as well as measuring binding affinity and stability of antibody-based biologics that bind with spike protein. GenScript also offers spike protein expressing HEK293T stable cell line (Cat. No. M00804) for SARS-CoV-2 study.
M00803
¥1,455,300.00

Ask us a question
Overview
Product Description Recombinant CHO-K1 cells stably overexpress human SARS-CoV-2 spike protein on their surface. The surface expression of SARS-CoV-2 spike protein is validated by FACS analysis. This stable cell line product is designed for screening antibodies against the SARS-CoV-2 spike protein, as well as measuring binding affinity and stability of antibody-based biologics that bind with spike protein. GenScript also offers spike protein expressing HEK293T stable cell line (Cat. No. M00804) for SARS-CoV-2 study.
Applications Cell-based binding assay; use as immunogen for antibody development

Product Introduction
Expressed Gene Codon optimized from NC_045512.2; no expressed tags
Target Protein YP_009724390.1
Host Cell CHO-K1
Size 2 vials of frozen cells (>1X106 per vial in 1 mL) 
Storage Store cells in liquid nitrogen immediately upon receipt. Thaw and recover cells within one year from the date received.
Mycoplasma Status Negative. The mycoplasma test was performed with MycoAlert™ PLUS Mycoplasma Detection Kit (Cat. No. LT07-318, Lonza).
Stability Stable through more than 15 passages with no significant changes in assay performance or expression profile. 

Culture Conditions
Culture Properties Adherent
Freeze Medium 95% complete growth medium, 5% DMSO (Cat. No. D2650, Sigma)
Complete Growth Medium Ham's F-12K (Kaighn's) Medium (Cat. No. 21127-022, Gibco), 10% FBS (Cat. No. 10099-141, Gibco)
Culture Medium Ham's F-12K (Kaighn's) Medium, 10% FBS (Cat. No. 10099-141, Gibco), 8 μg/mL Puromycin (Cat. No. A11138-03, Gibco) 

Background
Gene Synonyms S; spike glycoprotein
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell, the infecting RNA is used to encode structural proteins that make virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control, and accessory proteins whose function has not been determined. The structural proteins of SARS-CoV-2 include the envelope protein (E), spike or surface glycoprotein (S), membrane protein (M) and the nucleocapsid protein (N). The spike glycoprotein is found on the outside of the virus particle and gives coronaviruses their crown-like appearance. This glycoprotein mediates attachment of the virus particle and entry into the host cell. S protein is an important target for vaccine development, antibody therapies and diagnostic antigen-based tests.

Examples
  • CHO-K1/Spike Stable Cell Line
  • CHO-K1/Spike Stable Cell Line

    Figure 1: FACS analysis of cell surface expression of SARS-CoV-2 spike protein on CHO-K1 cells. CHO-K1/Spike cells (red) and negative control CHO-K1 cells (grey) were probed using ACE-2 Fc Chimera, Human (Cat. No. Z03516, GenScript) and Alexa Fluor 647 conjugated Goat anti-Human IgG (H+L) Cross-Adsorbed Secondary Antibody (Cat. No. A-21445, Thermo Fisher).